Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
170 hedge funds and large institutions have $1.53B invested in Arena Pharmaceuticals Inc in 2018 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 62 increasing their positions, 32 reducing their positions, and 11 closing their positions.
436% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 11
136% more call options, than puts
Call options by funds: $68.9M | Put options by funds: $29.2M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
94% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 32
56% more capital invested
Capital invested by funds: $978M → $1.53B (+$550M)
36% more funds holding
Funds holding: 125 → 170 (+45)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$83.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$45.9M |
| 3 |
BlackRock
New York
|
+$41M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$32.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25.1M |
| 3 |
Millennium Management
New York
|
-$16.4M |
| 4 |
Renaissance Technologies
New York
|
-$12.8M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$5.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCS
176
Crosspoint Capital Strategies
Orinda,
California
| – | -$155K | -456 | Closed |
|
|
RWA
177
Ropes Wealth Advisors
Boston,
Massachusetts
| – | -$9K | -260 | Closed |
|
178
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$7K | -200 | Closed |
|
|
CHP
179
Cable Hill Partners
Portland,
Oregon
| – | -$8K | -200 | Closed |
|
|
MA
180
MUFG Americas
New York
| – | -$6K | -177 | Closed |
|
ARNA Hedge Fund Activity: Q1 2018 in Review
170 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q1 2018, worth a combined $1.53B — up 56% from $978M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new ARNA positions and 11 closed out — a net gain of 48 holders — while 62 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $83.3M. The largest seller was Deerfield Management, cutting an estimated $32.1M.
- 170 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q1 2018, up from 125 in Q4 2017.
- Funds reported $1.53B of Arena Pharmaceuticals Inc stock for Q1 2018, up 56% quarter-over-quarter.
- 59 funds opened new Arena Pharmaceuticals Inc positions in Q1 2018 and 11 closed out, a net change of +48 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q1 2018 was Fidelity Investments, an estimated $83.3M added.
- The largest Arena Pharmaceuticals Inc seller in Q1 2018 was Deerfield Management, an estimated $32.1M sold.
Based on aggregated 13F filings for Q1 2018.